VIVEVE MEDICAL, INC. (NASDAQ:VIVE) Files An 8-K Results of Operations and Financial Condition

Item2.02. Results of Operations and Financial Condition.

On May 11, 2017, Viveve Medical, Inc. (the Company) issued a
press release announcing its results for the quarter ended March
31, 2017. A copy of the Companys press release is furnished as
Exhibit 99.1 to this report on Form 8-K.

The information in this Item 2.02 (including Exhibit 99.1) shall
not be deemed filed for purposes of Section 18 of the Securities
Exchange Act of 1934, as amended (the Exchange Act), or otherwise
subject to the liabilities of that section, nor shall it be
deemed incorporated by reference in any filing under the
Securities Act of 1933, as amended, or the Exchange Act,
regardless of any general incorporation language in such filing.

Item9.01. Financial Statements and Exhibits.

(d) Exhibits

About VIVEVE MEDICAL, INC. (NASDAQ:VIVE)

Viveve Medical, Inc., formerly PLC Systems, Inc., designs, develops, manufactures and markets medical devices for the non-invasive treatment of vaginal laxity. The Company’s Viveve Treatment is a non-invasive solution for vaginal laxity that is performed in approximately 30 minutes, in a physician’s office. The Viveve System uses monopolar radiofrequency (RF) energy to generate low temperature heat. The vaginal mucosa is simultaneously cooled while this non-ablative heat is delivered into the submucosal layer. The RF energy stimulates the formation of collagen and causes the collagen fibers to remodel thereby tightening the submucosal tissue of the vaginal introitus. The RF stimulation causes subtle alterations in the collagen that can renew the tissue and further tighten the vaginal tissue over the next 1 to 3 months following treatment (the Viveve Treatment) and lead to increased sexual function.

VIVEVE MEDICAL, INC. (NASDAQ:VIVE) Recent Trading Information

VIVEVE MEDICAL, INC. (NASDAQ:VIVE) closed its last trading session down -0.09 at 8.09 with 159,485 shares trading hands.